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Focal Thyroid Incidentalomas Identified with Whole-Body FDG-PET
Warrant Further Investigation
RS Prichard, M Cotter, D Evoy, D Gibbons, C Collins, E McDermott, S Skehan 
St Vincent’s University Hospital, Elm Park, Dublin 4
Abstract
Fluorodeoxyglucose (FDG) whole body positron emission computed tomography (PET-CT) detects clinically occult
malignancy. The aim of this study was to assess the prevalence and significance of focal thyroid 18F -
fluorodeoxyglucose uptake. A retrospective review of all patients who had FDG PET-CT examinations, in a single
tertiary referral centre was performed. PET scan findings and the final pathological diagnosis were collated. 2105
scans were reviewed. Focal uptake was identified in 35 (1.66%) patients. Final surgical histology was available on
eight patients, which confirmed papillary carcinoma in four (20%) patients and lymphoma and metastatic disease in two
patients respectively. This gave an overall malignancy rate in focal thyroid uptake of at least 33%. Thyroid
incidentalomas occurred with a frequency of 2.13 %, with an associated malignancy rate of at least 33% in focal
thyroid uptake. The high malignancy rate associated with focal thyroid uptake mandates further investigation in
medically fit patients. 
Introduction
Thyroid carcinoma remains the commonest endocrine malignancy and the National Cancer Registry in Ireland predicts a
rise its incidence, predominantly as a result of the increasing incidental detection of the disease1. Thyroid
incidentalomas are defined as new thyroid lesions identified on radiological grounds (ultrasound, CT, MRI, PET-CT) in
patients without a prior history of thyroid disease2. The relevance of these lesions remains unclear; however the
clinical dilemma is how to differentiate benign from malignant thyroid disease. The incidental finding of a thyroid
nodule is common. Palpable thyroid nodules have been identified in 4 â 7% of the population and the prevalence
increases to 19 â 67% when high resolution ultrasonography is utilized 3â5 . The majority of these lesions are benign
with a malignancy rate of approximately 1.5 â 10%3. 18F- FDG positron emission tomography is a combination technique
of functional (PET) and anatomical (CT) images to localize sites of increased metabolic activity6,7. As malignant and
inflammatory tissues exhibit increased rates of glycolysis and glucose uptake, they demonstrate more avid tracer
accumulation than normal tissues. PET-CT is being increasingly used for the staging and monitoring of patients with a
wide variety of known malignancies6. The aim of this study was to identify the prevalence of thyroid incidentalomas,
identified with PET-CT, in a single tertiary referral centre, to identify the rate of malignant disease occurring in
focal incidental thyroid uptake.
Methods
We retrospectively reviewed 2105 patientsâ scans that were performed in a single institution from January 2004 to
January 2009. Reports were searched electronically for the word âthyroidâ and these were reviewed to identify
cases with incidental thyroid uptake. The majority of PET-CT scans were performed for diagnosis or staging of patients
with known or suspected malignancy. There were no specific exclusion criteria. A total of 45 patients were identified
with focal or diffuse incidental uptake in the thyroid gland. Demographic data, data related to the PET scan, and
follow-up data were obtained for all patients in this study using electronic databases in the radiology and pathology
departments. The clinical significance of thyroid uptake was compared to the final histological diagnosis, either on
fine-needle aspiration cytology or on surgical excision specimens.  
PET scans were obtained on a dedicated whole body PET-CT scanner (Discovery LS, GE, Milwaukee, USA). All patients were
fasted, except for water, for 6 hours prior to their scan. A blood glucose level was taken prior to administration of
FDG, and insulin was administered to reduce elevated glucose if necessary. Image acquisition occurred 60 minutes
following intravenous injection of 370 MBq FDG. Standard coverage was either from skull base to upper thighs, skull
vault to upper thighs for head and neck primary tumours, or whole body for patients with melanoma. Typically this
required 4-7 bed positions. 3D acquisition was used, with reconstruction using OSEM. CT was performed without
intravenous contrast medium, with typical acquisition parameters of 120 kVp, 80mA and 3.8mm slice thickness. Oral
contrast medium was administered in a minority of cases, depending on the clinical indication for PET-CT. Data were
expressed as the percentage of focal and diffuse incidental thyroid FDG uptake among the study population.  
Results
Forty-five patients (35 female and 10 male, mean age: 61.9 years) were identified with incidental thyroid uptake from
the reports of the 2105 patientsâ scans that were retrospectively reviewed. This gave an overall prevalence of both
diffuse and focal thyroid incidentalomas of 2.13%. Of the 45 cases identified, 35 patients demonstrated focal thyroid
uptake giving a prevalence of 1.66%. The mean age of these patients was 64.4 years with a range of 31 to 90 years. The
majority of patients were female (n=26) and most lesions were identified in the right side of the gland (n=22). Ten
patients were identified with diffuse thyroid uptake, leading to a prevalence of 0.47%. The mean age of this group of
patients was younger at 59.4, with a range of 51 â 72 years and the majority were female (n=9).
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Figure 1: Management Guidelines for thyroid FDG-PET CT Incidentalomas
Of the 35 patients with focal thyroid uptake, 24 (68.6%) had a thyroid ultrasound performed. The reasons for failure
to further investigate focal increased thyroid uptake was the presence of diffuse metastatic disease in six patients
and poor overall medical condition in two patients. Twenty patients had a thyroid FNAC performed and of these, eight
patients underwent thyroid surgery (Table 1). Of the twenty patients who had a definitive pathological diagnosis two
had metastatic disease: one from a previously treated breast carcinoma and one from a known glottic squamous cell
carcinoma (10%); twelve patients had benign lesions (60%); four patients had a papillary carcinoma (20%) and a further
two patients had a lymphoma (10%) (Table 2). Of the ten patients who had diffuse thyroid uptake, six patients (60%)
had a thyroid ultrasound which demonstrated the presence of a multi-nodular goitre. No FNAC was performed on any
patient with diffuse thyroid uptake. 
Discussion
The detection of a thyroid nodule is a common clinical finding with a prevalence of between 4 â 7% in North
America17. However, what remains important is to identify which of these lesions will prove to be malignant. A thyroid
incidentaloma is defined as a newly identified thyroid lesion encountered during an imaging study for non-thyroidal
disease2. The use of high-resolution ultrasonography identifies these lesions in 19 â 67% of the population. The
majority are benign with a malignancy rate of only 1.5 â 10%3â5. PET scanning using 18 F-FDG is a non-invasive
whole-body imaging technique which provides functional evidence of disease. It preferentially detects malignant
lesions as a result of increased glycolysis and cellular proliferation6,7. The current prevalence of PET uptake in the
thyroid (focal and diffuse) is between 0.4 â 8.9% 8â16 . The incidence of incidental thyroid uptake in this study was
2.13%, which is within the range reported in literature. Increasing numbers of patients with thyroid uptake of FDG
will be identified in tandem with increasing use of this imaging modality. 
The reported incidence of focal thyroid FDG uptake is 1.2 â 4.3% 8â14 . Of these lesions, a malignancy rate of between
14 â 57% has been reported, which is higher than with other imaging modalities 9â15 . This study demonstrated an
overall malignancy rate of at least 33%. There are a number of proposed reasons for the higher rate of malignancy with
this form of imaging. Firstly, most PET-CT scans are performed in patients who already have a diagnosis of cancer and
therefore there is a high pre-test probability of a second carcinoma being detected7. Secondly, patients with focal
thyroid uptake were significantly older than those with diffuse uptake which may represent the increasing incidence of
papillary thyroid carcinoma with age. Thirdly, PET-CT is a functional imaging modality which identifies early
malignant disease due to the increased utilization of glucose in malignant cells. Finally, most published data is
retrospective, with a small cohort of patients who have final histological diagnoses which may alter the final
incidence of malignant disease. However, given the high associated risk of malignancy in focal thyroid incidentalomas,
further diagnostic work-up should be considered in all surgically fit patients.
In direct comparison, our rate of diffuse uptake was 0.47% which is similar to previous reports of diffuse thyroid FDG
uptake of between 0.4 â 8.9% 15,16. However, it is much less likely to be malignant. Studies by both Yasuda et al and
Karantanis et al demonstrated that diffuse uptake is predominantly due to chronic lymphocytic thyroiditis
(Hashimotoâs) with a small number being due to Gravesâ disease 15,18. While analysis of thyroid function would be
advantageous this was not performed due to the retrospective nature of this study. Therefore, the management of
diffuse and focal thyroid lesions should be different based on the underlying risk of malignancy (Figure 1).
The majority of thyroid carcinomas that have been identified in other studies have occurred in woman and have been
papillary in nature. This study demonstrates similar results with all cancers occurring in women and all four primary
thyroid carcinomas were papillary. It is important to note that the presence of a solitary thyroid nodule may be due
to metastatic disease. Although the thyroid gland is an uncommon site of secondary carcinoma deposits, this series has
demonstrated that two patients, with focal thyroid uptake of 18F â FDG had metastatic disease (10%) 19. Therefore,
while focal thyroid uptake of FDG should be considered to be more likely to represent a second primary tumour the
presence of metastatic disease should also be considered. We do however accept that there may be a degree of selection
bias due to the fact that the majority of PET scans were performed for patients with pre-existing malignant disease.
This study used ultrasound guided final needle aspiration cytology to obtain a pre-operative histological diagnosis.
This is a sensitive test with a false negative rate of 0.7 â 2.4% and an accuracy rate of 95% 20.
However, it is often limited by the ability to obtain enough tissue to make a diagnosis and the difficulty in
differentiating benign and malignant follicular lesions. In this series, within the focal thyroid uptake group, two
patients had a thyroid lobectomy performed for a follicular and a Hurthle cell adenoma respectively. All five patients
with a pre-operative T4 FNAC had malignant disease as did the one patient who had a T5 diagnosis. A limitation of this
study is the difficult in accurately predicting the sensitivity of PET-CT as eight patients with a Thy 3 follicular
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lesion did not undergo surgical excision. This study has a number of limitations, primarily as a result of its
retrospective nature. Firstly, in total there are only a small number of patients with either focal or diffuse uptake
(n=45; 2.13%).  Secondly, of the focal lesions that were identified only 57% had further imaging and a histological
diagnosis obtained. This may therefore obscure the real incidence of malignancy in PET positive lesions, but it
reflects a complex patient population in whom detection of a possible small thyroid neoplasm may not always be
clinically relevant. 
This study demonstrates that incidental focal thyroid uptake identified on PET-CT occurs in 1.66% of all scans and has
as associated malignancy rate of at least 33%, significantly higher than the malignancy rate for thyroid nodules
detected by any other means. Further investigation with FNA and US guided biopsy is mandatory in surgically fit
patients. While it is reassuring that diffuse thyroid uptake is not considered to be related to malignancy it would
however, be prudent to at least perform a thyroid ultrasound. The accurate identification of the risk of malignancy in
focal thyroid lesions is important as the number of carcinomas identified in this manner is set to increase, utilizing
significant resources, as the use of PET-CT becomes more widespread. 
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